HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability

Molecular Cell

Volumn 12, Issue 3, 2003, Pages 591-601

  Stopak, Kim ^a   De Noronha, Carlos ^a   Yonemoto, Wes ^a   Greene, Warner C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; APOLIPOPROTEIN B MRNA EDITING ENZYME; ENZYME; MESSENGER RNA; PROTEASOME; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DEPLETION; ENZYME DEGRADATION; ENZYME STABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRACELLULAR SPACE; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PROCESSING; T LYMPHOCYTE; TRANSLATION INITIATION; VIRION; VIRUS INFECTIVITY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0141638436     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(03)00353-8     Document Type: Article

References (30)

1. Adachi A., Ono N., Sakai H., Ogawa K., Shibata R., Kiyomasu T., Masuike H., Ueda S. Generation and characterization of the human immunodeficiency virus type 1 mutants. Arch. Virol. 117:1991;45-58.
2. Bonneau A.M., Sonenberg N. Proteolysis of the p220 component of the cap-binding protein complex is not sufficient for complete inhibition of host cell protein synthesis after poliovirus infection. J. Virol. 61:1987;986-991.
3. Bovee M.L., Marissen W.E., Zamora M., Lloyd R.E. The predominant elF4G-specific cleavage activity in poliovirus-infected HeLa cells is distinct from 2A protease. Virology. 245:1998;229-240.
4. Boyer S.N., Wazer D.E., Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56:1996;4620-4624.
5. Bresnahan P.A., Yonemoto W., Ferrell S., Williams-Herman D., Geleziunas R., Greene W.C. A dileucine motif in HIV-1 Nef acts as an internalization signal for CD4 downregulation and binds the AP-1 clathrin adaptor. Curr. Biol. 8:1998;1235-1238.
6. Chatton B., Bahr A., Acker J., Kedinger C. Eukaryotic GST fusion vector for the study of protein-protein associations in vivo. application to interaction of ATFa with Jun and Fos Biotechniques. 18:1995;142-145.
7. DesRosiers R.C., Lifson J.D., Gibbs J.S., Czajak S.C., Howe A.Y., Arthur L.O., Johnson R.P. Identification of highly attenuated mutants of simian immunodeficiency virus. J. Virol. 72:1998;1431-1437.
8. Dettenhofer M., Yu X.F. Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. J. Virol. 73:1999;1460-1467.
9. Didcock L., Young D.F., Goodbourn S., Randall R.E. The V protein of simian virus 5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated degradation. J. Virol. 73:1999;9928-9933.
10. Eckstein D.A., Sherman M.P., Penn M.L., Chin P.S., de Noronha C.M., Greene W.C., Goldsmith M.A. HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells. J. Exp. Med. 194:2001;1407-1419.
11. Etchison D., Milburn S.C., Edery I., Sonenberg N., Hershey J.W. Inhibition of HeLa cell protein synthesis following poliovirus infection correlates with the proteolysis of a 220,000-dalton polypeptide associated with eucaryotic initiation factor 3 and a cap binding protein complex. J. Biol. Chem. 257:1982;14806-14810.
12. Fisher A.G., Ensoli B., Ivanoff L., Chamberlain M., Petteway S., Ratner L., Gallo R.C., Wong-Staal F. The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science. 237:1987;888-893.
13. Gabuzda D.H., Lawrence K., Langhoff E., Terwilliger E., Dorfman T., Haseltine W.A., Sodroski J. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J. Virol. 66:1992;6489-6495.
14. Goncalves J., Jallepalli P., Gabuzda D.H. Subcellular localization of the Vif protein of human immunodeficiency virus type 1. J. Virol. 68:1994;704-712.
15. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., Malim M.H. DNA deamination mediates innate immunity to retroviral infection. Cell. 113:2003;803-809.
16. Harris R.S., Petersen-Mahrt S.K., Neuberger M.S. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell. 10:2002;1247-1253.
17. Khan M.A., Aberham C., Kao S., Akari H., Gorelick R., Bour S., Strebel K. Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J. Virol. 75:2001;7252-7265.
18. Kuyumcu-Martinez N.M., Joachims M., Lloyd R.E. Efficient cleavage of ribosome-associated poly(A)-binding protein by enterovirus 3C protease. J. Virol. 76:2002;2062-2074.
19. Lecossier D., Bouchonnet F., Clavel F., Hance A.J. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science. 300:2003;1112.
20. Madani N., Kabat D. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J. Virol. 72:1998;10251-10255.
21. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 424:2003;99-103.
22. Mariani R., Chen D., Schrofelbauer B., Navarro F., Konig R., Bollman B., Munk C., Nymark-McMahon H., Landau N.R. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 114:2003;21-31.
23. Sakai H., Shibata R., Sakuragi J., Sakuragi S., Kawamura M., Adachi A. Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J. Virol. 67:1993;1663-1666.
24. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 418:2002;646-650.
25. Simon J.H., Gaddis N.C., Fouchier R.A., Malim M.H. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat. Med. 4:1998;1397-1400.
26. Sova P., Volsky D.J. Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J. Virol. 67:1993;6322-6326.
27. Strebel K., Daugherty D., Clouse K., Cohen D., Folks T., Martin M.A. The HIV 'A' (sor) gene product is essential for virus infectivity. Nature. 328:1987;728-730.
28. von Schwedler U., Song J., Aiken C., Trono D. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J. Virol. 67:1993;4945-4955.
29. Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 424:2003;94-98.
30. Zimmermann H., Degenkolbe R., Bernard H.U., O'Connor M.J. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J. Virol. 73:1999;6209-6219.